Chronic Myelogenous Leukemia

What Is Chronic Myelogenous Leukemia?

Chronic myelogenous leukemia (CML) is a type of blood cancer that starts in the bone marrow and leads to the overproduction of abnormal white blood cells. It develops slowly over time and is considered a chronic leukemia. These abnormal cells can accumulate in the blood and crowd out healthy blood cells, affecting the body’s ability to fight infections, carry oxygen, and control bleeding.

CML is strongly associated with a specific genetic abnormality known as the Philadelphia Chromosome, which drives the uncontrolled growth of leukemia cells.

What Happens in the Body

In CML, a genetic change in bone marrow stem cells creates the Philadelphia chromosome, which produces an abnormal protein (BCR-ABL). This protein acts as a constantly active signal that tells cells to grow and divide uncontrollably.

As a result:

Large numbers of immature and mature white blood cells build up in the blood
Normal production of red blood cells and platelets may be disrupted
The spleen may enlarge as it filters excess cells

Over time, if untreated, CML can progress from a slow-growing phase to more aggressive stages.

Phases of CML

CML typically progresses through three phases:

Chronic phase:
The earliest and most stable phase. Many people have mild or no symptoms, and the disease is often found on routine blood tests.
Accelerated phase:
The disease begins to progress, with rising numbers of abnormal cells and worsening symptoms.
Blast phase (blast crisis):
A more aggressive phase resembling acute leukemia, with large numbers of immature cells (blasts). This phase is more difficult to treat.

Common Symptoms

Symptoms can be mild at first and may develop gradually:

Fatigue and weakness
Unexplained weight loss
Night sweats
Fever without infection
Fullness or discomfort in the left upper abdomen (due to an enlarged spleen)
Easy bruising or bleeding
Shortness of breath

The severity of symptoms often increases as the disease progresses.

Causes and Risk Factors

CML is caused by an acquired genetic mutation, not an inherited condition. In most cases, there is no clear trigger. Known associations include:

Spontaneous genetic changes in bone marrow cells
Exposure to high levels of radiation

CML does not typically run in families and is not passed from parents to children.

Diagnosis

Diagnosis is based on blood tests and genetic analysis:

Complete Blood Count (CBC): Shows elevated white blood cell counts, often with immature forms
Peripheral blood smear: Reveals abnormal white blood cell development
Bone Marrow Biopsy: Confirms increased white blood cell production in the marrow
Genetic testing: Detects the Philadelphia chromosome or BCR-ABL gene

These tests help confirm the diagnosis and determine the phase of the disease.

Treatment Options

Treatment for CML has improved significantly and is highly effective for many patients:

Targeted therapy (tyrosine kinase inhibitors, TKIs):
Medications such as imatinib, dasatinib, and nilotinib specifically block the BCR-ABL protein. These are the standard first-line treatments and can control the disease for many years.
Bone marrow (stem cell) transplant:
A potentially curative option but used less commonly today, typically in cases where targeted therapy is not effective or in advanced disease.
Chemotherapy:
May be used in certain situations, especially in advanced phases.
Supportive care:
Includes treatments to manage symptoms, infections, or complications.

Outlook and Monitoring

With modern targeted therapies, most people with CML—especially when diagnosed in the chronic phase—can achieve long-term disease control and near-normal life expectancy.

Regular monitoring is essential and typically includes blood tests and measurement of BCR-ABL levels to assess how well treatment is working.

In some cases, patients who achieve a deep and sustained response may be able to reduce or stop therapy under close medical supervision.

Why It Matters

Chronic myelogenous leukemia is a clear example of how a single genetic change can drive cancer development. Early diagnosis and access to effective targeted therapies have transformed CML from a life-threatening disease into a manageable chronic condition for many people.

If you have persistent fatigue, unexplained weight loss, or abnormal blood test results, discussing further evaluation with your doctor can help ensure early detection and appropriate care.